ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health policy"

  • Abstract Number: 1019 • ACR Convergence 2023

    Association of Historical Redlining and Present-Day Neighborhood Inequities with Missed Outpatient Appointments Among Individuals with Rheumatic Conditions

    Sherry Yang1, Leah Santacroce2 and Candace Feldman2, 1Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Structural racism pervades U.S. history with continued effects on health inequities. Residential segregation serves as an example, where redlining maps outlined areas with high…
  • Abstract Number: 1616 • ACR Convergence 2023

    Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies

    Joshua Skydel1, Reshma Ramachandran2, Sakinah Suttiratana2, Joseph Ross2, Joshua Wallach3 and Christopher Burns4, 1Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Yale University, New Haven, CT, 3Emory University, Atlanta, GA, 4Dartmouth Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
  • Abstract Number: 2019 • ACR Convergence 2023

    2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

    Emma Dures1, Bayram Farisogullari2, Eduardo Santos3, Anna Molto4, Caroline Feldthusen5, Claire Harris6, Corinna Elling-Audersch7, Deirdre Conolly8, Elena Elefante9, Fernando Estévez-López10, Ilaria Bini11, Jette Primdahl12, Kirsten Hoeper13, Marie Urban14, Mart van de Laar15, Marta Redondo16, Peter Böhm17, Raj Amarnani18, Rhys Hayward6, Rinie Geenen19, Simona Rednic20, Susanne Pettersson21, Tanja Thomsen22, Till Uhlig23, Valentin Ritschl24 and Pedro Machado25, 1Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 3Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, 4HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 5Institute of Neuroscience and Physiology, University of Gothenburg, Department of Health and Rehabilitation, Unit of Physiotherapy, Sahlgrenska Academy, Gothenburg, Sweden, 6Northwick Park Hospital, London North West University Healthcare NHS Trust, Department of Rheumatology, London, United Kingdom, 7Deutsche Rheuma-Liga Bundesverband e.V., Patient Research Partner, Bonn, Germany, 8School of Medicine, Trinity College Dublin, Discipline of Occupational Therapy, Dublin, Ireland, 9Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 10Harvard T.H. Chan School of Public Health, Department of Social and Behavioral Sciences, Boston, MA, 11Anmar, Young, Rome, Italy, Rome, Italy, 12University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 13Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany, 14University Hospitals Bristol, Research Design Service, Bristol, United Kingdom, 15University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, 16Camilo José Cela University, Faculty of Heath Sciences, Madrid, Spain, 17German League against rheumatism, Forschungspartner, Bonn, Germany, 18Barts Health NHS Trust, Barts Health Rheumatology Service, London, United Kingdom, 19Utrecht University, Vorstenbosch, Netherlands, 20Prof Dr Simona Rednic, Cluj, Romania, 21Karolinska Institute, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 22University of Copenhagen, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases VRR, Rigshospitalet, Copenhagen, Denmark, 23Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 24Medical University of Vienna, Vienna, Austria, 25Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom

    Background/Purpose: Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognized as one of the most challenging symptoms to manage (1).…
  • Abstract Number: 2283 • ACR Convergence 2023

    Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness

    Arthur Mageau1, Julia Simard2, Elisabet Svenungsson3 and Elizabeth Arkema4, 1Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, 2Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, 3Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 4Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
  • Abstract Number: 2480 • ACR Convergence 2023

    Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI

    Victoria Konzett1, Andreas Kerschbaumer2, Josef S Smolen3, Eirik Kristianslund4, Sella Provan4, Tore Kvien5 and Daniel Aletaha6, 1Medical University of Vienna, Wien, Austria, 2Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 4Diakonhjemmet Hospital, Oslo, Norway, 5Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria

    Background/Purpose: Measures of improvement and state of disease activity are well-established in rheumatoid arthritis (RA), whereas distinct classifiers for worsening (“flare”) are lacking to date.…
  • Abstract Number: 0159 • ACR Convergence 2023

    Understanding the Economic Impact of Autoimmune Eye Disease in the United States

    Krati Chauhan1, Steven Scaife2 and Michael Buhnerkempe1, 1Southern Illinois University - School of Medicine, Springfield, IL, 2Southen Illinois University - School of Medicine., Springfield, IL

    Background/Purpose: Eye involvement is an important cause of morbidity in rheumatology patients. Inflammatory eye diseases include conditions like scleritis, uveitis, retinitis and orbital inflammation. The…
  • Abstract Number: 0161 • ACR Convergence 2023

    Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe

    Brigitte Michelsen1, Mikkel Østergaard2, Michael Nissen3, Adrian Ciurea4, Burkhard Moeller5, Lykke Ørnbjerg6, Jakub Zavada7, Bente Glintborg8, Alan MacDonald9, Karin Laas10, Dan Nordstrom11, Bjorn Gudbjornsson12, Florenzo Iannone13, Pasoon Hellamand14, Tore Kvien15, Ana Maria Rodrigues16, Catalin Codreanu17, Ziga Rotar18, Isabel Castrejon19, Johan Karlsson Wallman20, Jiri Vencovsky21, Anne Gitte Loft22, Maureen Heddle23, Sigrid Vorobjov24, Anna-Mari Hokkanen25, Gerdur Maria Grondal26, Marco Sebastiani27, Marleen van de Sande28, Eirik Kristianslund29, Maria Jose Santos30, Corina Mogosan31, Matija Tomsic32, Jose Federico Diaz-Gonzalez33, Daniela Di Giuseppe34 and Merete Hetland6, 1Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 3Geneva University Hospitals, Geneva, Switzerland, 4University Hospital Zurich, Zürich, Switzerland, 5Inselspital - University Hospital Bern, Bern, Switzerland, 6Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 7Institute of Rheumatology; Charles University, Prague, Czech Republic, 8Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, 9NHS Grampian, Aberdeen, United Kingdom, 10Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, 11Helsinki University Hospital, Helsinki, Finland, 12Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 13Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 14Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 15Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 16Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, 17Center for Rheumatic Diseases, Bucharest, Romania, 18University Medical Centre Ljubljana, Ljubljana, Slovenia, 19Hospital General Universitario Gregorio Marañón, Madrid, Spain, 20Lund University and Skåne University Hospital, Lund, Sweden, 21Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 22Aarhus University, Horsens, Denmark, 23Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, 24National Institute for Health Development, Tallinn, Estonia, 25Helsinki University and Helsinki University Hospital, Helsinki, Finland, 26Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 27Azienda Policlinico di Modena, Modena, Italy, 28Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, 29Diakonhjemmet Hospital, Oslo, Norway, 30Hospital Garcia de Orta, Almada, Lisboa, Portugal, 31University of Medicine and Pharmacy, Bucharest, Romania, 32University Medical Centre Ljubljana; Universitiy of Ljubljana, Ljubliana, Slovenia, 33Hospital Universitario de Canarias, La Laguna, Spain, 34Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…
  • Abstract Number: 0175 • ACR Convergence 2023

    Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach

    Ashkan Ara1, Matthew Chenoweth1 and Christopher Scannell2, 1University of California Los Angeles, Los Angeles, CA, 2UCLA / West Los Angeles VA Medical Center, Los Angeles, CA

    Background/Purpose: Cost-related medication non-adherence (CRN) occurs when patients are unable to follow their prescribed medication regimen due to financial constraints, such as high costs or…
  • Abstract Number: 0177 • ACR Convergence 2023

    Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities

    Ashkan Ara1, Matthew Chenoweth1, Christopher Scannell2 and John FitzGerald1, 1University of California Los Angeles, Los Angeles, CA, 2UCLA / West Los Angeles VA Medical Center, Los Angeles, CA

    Background/Purpose: Cost-related medication non-adherence (CRN), a measure of drug affordability, refers to a patient's inability to adhere to a prescribed medication regimen due to high…
  • Abstract Number: 0198 • ACR Convergence 2023

    Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership

    Stephen Lindsey1, Brittany Hill2, Sheela Sheth3 and Arya Loghmani2, 1LSU Health Science Center, New Orleans, LA, 2Louisiana State University, New Orleans, LA, 3Tulane University, New Orleans, LA

    Background/Purpose: Herpes zoster (HZ), also known as shingles, causes an estimated one million cases annually in the United States. Many studies have shown that the…
  • Abstract Number: 0217 • ACR Convergence 2023

    Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study

    Tali Eviatar1, Victoria Furer2, Ilana Kaufman3, David levartovsky2, Ofir Elalouf2, Devy Zisman4, Tal Gazitt5, Amir Haddad4, Muna Elias6, Joy Feld7, Alexandra Balbir-Gurman8, Yolanda Braun Moscovici9, Sara Pel10, sharon Nevo11, Daphna Paran2 and Ori Elkayam2, 1Tel Aviv Sourasky Medical center, Ramat Gan, Israel, 2Tel Aviv Medical Center, Tel Aviv, Israel, 3Tel Aviv Medical Center, Petah-Tikva, Israel, 4Carmel Medical Center, Haifa, Israel, 5Carmel Hospital, Haifa, Israel, 6rheumatology unit, Haifa, Israel, 7Carmel and Zvulun Medical Centre, Haifa, Israel, 8Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 9Rambam Heath Care Campus, Haifa, Israel, 10Tel Aviv Medical Center, Modiin, Israel, 11Tel Aviv Sourasky Medical Center, Givataim, Israel

    Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
  • Abstract Number: 0465 • ACR Convergence 2023

    The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists

    Mehret Birru Talabi1, Bonnie Bermas2, Irene Blanco3, Ashira Blazer4, Megan Clowse5, Cuoghi Edens6, Leslie Pierce7, Catherine Wright1 and Rosalind Ramsey-Goldman3, 1University of Pittsburgh, Pittsburgh, PA, 2UT Southwestern, Dallas, TX, 3Northwestern University, Chicago, IL, 4Hospital for Special Surgery, New York, NY, 5Duke University, Chapel Hill, NC, 6University of Chicago, Chicago, IL, 7University of Pittsburgh, Raleigh, NC

    Background/Purpose: In June 2022, the U.S. Supreme Court's decision in Dobbs v. Jackson Women's Health removed the federal constitutional right to abortion, returning abortion policy…
  • Abstract Number: 084 • 2023 Pediatric Rheumatology Symposium

    Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic

    Kristiana Nasto1, David McDonald1, Kyla Fergason1, Mary Robichaux1, Bernard Danna1, Monique Maher1, Alexander Alexander1, Danielle Guffey1, Miriah Gillispie-Taylor2 and Tiphanie Vogel1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Transition of adolescents with chronic healthcare needs to adult care may result in poor outcomes. We have developed a program to improve the transition…
  • Abstract Number: L09 • ACR Convergence 2022

    Impact on Access to Methotrexate in the Post-Roe Era

    Kristin Wipfler1, Adam Cornish1, Rebecca Schumacher2, Yomei Shaw3, Patricia Katz4 and Kaleb Michaud5, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 3FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, 4UCSF, San Rafael, CA, 5University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…
  • Abstract Number: 0227 • ACR Convergence 2022

    The Rheumatology Workforce: Analyzing Geographic and Temporal Variations Among the Rheumatology Physician Workforce in the United States

    Kavish Singh1, Lynn Foster-Johnson2, Sladjana Skopelja-Gardner3, Arabi Rasendrakumar4, Temitope Ajayi5 and Aakanksha Khanna6, 1Montefiore Medical Center, Brooklyn, NY, 2Dartmouth Geisel School of Medicine, Lebanon, NH, 3Dartmouth Hitchcock Medical Center, Lebanon, NH, 4University of Buffalo, Buffalo, NY, 5University at Buffalo, Buffalo, NY, 6Dartmouth-Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: To analyze recent trends in the rheumatology workforce related to temporal and national geographic variation in the United States (US). Methods: The publicly available physician workforce…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology